

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

[X] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *			2. Issuer Name and Ticker or Trading Symbol			5. Relationship of Reporting Person(s) to Issuer (Check all applicable)		
CB Biotech Investment Ltd			BeiGene, Ltd. [BGNE]			<input type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner <input type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below)		
(Last) (First) (Middle)			3. Date of Earliest Transaction (MM/DD/YYYY)					
C/O MAPLES CORPORATE SERVICES (BVI) LTD., KINGSTON CHAMBERS, P.O. BOX 173 RD. TOWN			2/8/2016					
(Street)			4. If Amendment, Date Original Filed (MM/DD/YYYY)			6. Individual or Joint/Group Filing (Check Applicable Line)		
TORTOLA, D8						<input type="checkbox"/> Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person		
(City) (State) (Zip)								

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Ordinary Shares	2/8/2016		C		19601138 (1)	A	\$0	19601138 (2)	D	

Table II - Derivative Securities Beneficially Owned (e.g. , puts, calls, warrants, options, convertible securities)

1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Series A Preferred Shares	(3)	2/8/2016		C		14814814		(3)	(3)	Ordinary Shares	14814814	\$0	0	D	
Series A-2 Preferred Shares	(4)	2/8/2016		C		4786324		(4)	(4)	Ordinary Shares	4786324	\$0	0	D	

Explanation of Responses:

- Represents the total number of Ordinary Shares received upon conversion of the Issuer's Series A Preferred Shares and Series A-2 Preferred Shares.
- CB Biotech Investment Limited ("CB Biotech") directly owns 19,601,138 Ordinary Shares. CB Biotech is wholly owned by CPEChina Fund, L.P. ("CPEC"), and CITIC PE Associates, L.P. ("PE Associates") is the sole general partner of CPEC. CITIC PE Funds Limited ("PE Funds") is the sole general partner of PE Associates. The shares directly owned by CB Biotech may be deemed indirectly owned by CPEC, PE Associates, and PE Funds (the "Reporting Persons"); however, each Reporting Person disclaims beneficial ownership of these securities except to the extent of its respective pecuniary interest therein, if any, and the inclusion of these shares in their report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or any other purpose.
- Immediately prior to the closing of the Issuer's initial public offering of its American Depositary Shares, each representing 13 Ordinary Shares ("the ADSs"), the 14,814,814 shares of Series A Preferred Shares were converted into the number of Ordinary Shares shown in Column 7. The Series A Preferred Shares did not have an expiration date and the shares were convertible, at any time, at the holder's election, into Ordinary Shares of the Issuer.
- Immediately prior to the closing of the Issuer's initial public offering of its ADSs, the 4,786,324 shares of Series A-2 Preferred Shares were converted into the number of Ordinary Shares shown in Column 7. The Series A-2 Preferred Shares did not have an expiration date and the shares were convertible, at any time, at the holder's election, into Ordinary Shares of the Issuer.

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
CB Biotech Investment Ltd				

C/O MAPLES CORPORATE SERVICES (BVI) LTD. KINGSTON CHAMBERS, P.O. BOX 173 RD. TOWN TORTOLA, D8		X		
CPEChina Fund, L.P. C/O MAPLES CORPORATE SERVICES (BVI) LTD. KINGSTON CHAMBERS, P.O. BOX 173 RD. TOWN TORTOLA, D8		X		
CITIC PE Associates, L.P. C/O MAPLES CORPORATE SERVICES (BVI) LTD. KINGSTON CHAMBERS, P.O. BOX 173 RD. TOWN TORTOLA, D8		X		
CITIC PE Funds Ltd C/O MAPLES CORPORATE SERVICES (BVI) LTD. KINGSTON CHAMBERS, P.O. BOX 173 RD. TOWN TORTOLA, D8		X		

Signatures

/s/ Ching Nar Cindy Chan 2/9/2016

**Signature of Reporting Person

Date

/s/ Ching Nar Cindy Chan 2/9/2016

**Signature of Reporting Person

Date

/s/ Ching Nar Cindy Chan 2/9/2016

**Signature of Reporting Person

Date

/s/ Ching Nar Cindy Chan 2/9/2016

**Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.